Arrowhead Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapeutics aimed at treating diseases through RNA interference (RNAi) technology. The company's primary goal is to create targeted treatments that can silence specific genes associated with various diseases, particularly in the areas of liver diseases, cancer, and cardiovascular conditions. Arrowhead's proprietary platform allows for the design of treatments that can effectively deliver small interfering RNA (siRNA) to relevant tissues, potentially leading to transformative therapies that address unmet medical needs. Through its research and development efforts, Arrowhead aims to advance its pipeline of drug candidates and bring novel solutions to the market for patients suffering from challenging health conditions.
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT). Here's what you need to know.
Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it presented preclinical data on ARO-INHBE.
Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.
